Press releases
  • NEW YORK
  • May 20, 2020

Tarus Therapeutics Strengthens Board of Directors with the Appointment of Preeminent Life Sciences Industry Leaders

Tarus Therapeutics Inc., an innovative biotechnology company, announced the appointments of David R. Epstein and C. David Nicholson, PhD, to its Board of Directors, effective May 14, 2020

  • by Accesswire
  • Dec 23, 2019

A licensing deal with Impetis Biosciences, Ltd.

Tarus Therapeutics, Inc., (Tarus) and Impetis Biosciences, Ltd., (Impetis), announced today that Tarus has taken an IP license from Impetis to develop a portfolio of adenosine receptor antagonists for cancer immunotherapy as well as non-cancer indications.